TY - JOUR
T1 - Treatments for hepatitis B
AU - Asmuth, David
AU - Nguyen, Hien H
AU - Melcher, Gregory P.
AU - Cohen, Stuart H
AU - Pollard, Richard B
PY - 2004/11/1
Y1 - 2004/11/1
N2 - New optimism surrounds treatments for chronic hepatitis B (CHB). Interferon-α, lamivudine, and adefovir dipivoxil are currently approved by the United States Food and Drug Administration for the treatment of CHB. All 3 treatments possess unique characteristics with respect to their side effect profiles, potencies, and treatment niches within the spectrum of CHB. New agents, which are in various stages of clinical development, represent potential improvements within existing, as well as novel, classes of antiviral therapy, and they offer significant promise of a cure for the many patients with chronic and progressive hepatitis B. However, there remain many challenges in understanding the implications of drug resistance, the role of combination therapy, and how to define the response to therapy within subsets of patients with hepatitis B.
AB - New optimism surrounds treatments for chronic hepatitis B (CHB). Interferon-α, lamivudine, and adefovir dipivoxil are currently approved by the United States Food and Drug Administration for the treatment of CHB. All 3 treatments possess unique characteristics with respect to their side effect profiles, potencies, and treatment niches within the spectrum of CHB. New agents, which are in various stages of clinical development, represent potential improvements within existing, as well as novel, classes of antiviral therapy, and they offer significant promise of a cure for the many patients with chronic and progressive hepatitis B. However, there remain many challenges in understanding the implications of drug resistance, the role of combination therapy, and how to define the response to therapy within subsets of patients with hepatitis B.
UR - http://www.scopus.com/inward/record.url?scp=7644242419&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=7644242419&partnerID=8YFLogxK
U2 - 10.1086/425010
DO - 10.1086/425010
M3 - Article
C2 - 15494913
AN - SCOPUS:7644242419
VL - 39
SP - 1353
EP - 1362
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - 9
ER -